Sentiss

Executive Summary

Sentiss is a privately held Indian biotech founded in 2020, focused on developing innovative sustained-release therapeutics for ophthalmic disorders, particularly diabetic retinopathy and age-related macular degeneration. Leveraging a proprietary ocular drug-delivery platform, the company aims to address the large and growing Indian eye-care market with affordable, high-impact solutions. Currently in preclinical stage, Sentiss has not disclosed specific lead candidates or funding amounts, but its platform holds potential for improved patient compliance and outcomes. The company operates in a segment with high unmet medical need and increasing prevalence of retinal diseases in India. However, as a preclinical entity, Sentiss faces significant technical and regulatory risks, and its valuation and pipeline details remain limited. The private nature and early stage constrain visibility, but the targeted market opportunity and platform approach warrant attention. Sentiss's progress in advancing its preclinical programs and securing partnerships or financing will be key milestones to watch.

Upcoming Catalysts (preview)

• H2 2026Completion of lead candidate preclinical studies70% success
• H1 2027IND filing for first candidate40% success
• 2026Strategic partnership or series A funding30% success